abstract |
The present disclosure provides methods of inhibiting an immune response to a viral vector used in gene therapy, such as adeno-associated virus (AAV), which involves co-administration of viral vector and an interfering molecule. The interfering molecule functions by either disrupting the TLR9-MyD88-type I IFN signaling pathway and/or neutralizing Type I IFNs, thereby inhibiting the immune response directed against the viral vector. The methods additionally encompass the step of re-administering the viral vector. |